Condition: Renal Cell Carcinoma (RCC) · Metastatic Castration-Resistant Prostate Cancer (mCRPC) · Urothelial Carcinoma (UC) · Sponsor: Exelixis
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) in participants with advanced solid tumors. In the Expansion Stage, the safety and efficacy of zanzalintinib as monotherapy and in combination therapy will be further evaluated in tumor-specific Expansion Cohorts.
This description comes directly from the study's public registry record.
Exelixis Clinical Trials · 1-888-EXELIXIS (888-393-5494) · druginfo@exelixis.com
Backup or International · 650-837-7400
Always discuss trial participation with your own doctor first.
| Exelixis Clinical Site #67 | Phoenix, Arizona, United States | Recruiting |
| Exelixis Clinical Site #1 | Tucson, Arizona, United States | Recruiting |
| Exelixis Clinical Site #123 | Palo Alto, California, United States | Recruiting |
| Exelixis Clinical Site #59 | Santa Barbara, California, United States | Recruiting |
| Exelixis Clinical Site #87 | Littleton, Colorado, United States | Recruiting |
| Exelixis Clinical Site #62 | New Haven, Connecticut, United States | Recruiting |
| Exelixis Clinical Site #49 | Newark, Delaware, United States | Active Not Recruiting |
| Exelixis Clinical Site #48 | Celebration, Florida, United States | Recruiting |
| Exelixis Clinical Site #11 | Gainesville, Florida, United States | Recruiting |
| Exelixis Clinical Site #78 | Jacksonville, Florida, United States | Recruiting |
| Exelixis Clinical Site #47 | Miami, Florida, United States | Recruiting |
| Exelixis Clinical Site #61 | Plantation, Florida, United States | Recruiting |
+ 110 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05176483